Yayın:
Comparison of the neuroprotective effects of gossypin on cisplatin-induced neurotoxicity in vitro and in vivo

dc.contributor.authorCinar, Irfan
dc.contributor.authorYayla, Muhammed
dc.contributor.authorBayram, Pınar
dc.contributor.authorBinnetoğlu, Damla
dc.date.accessioned2026-01-04T20:42:44Z
dc.date.issued2024-07-19
dc.description.abstract<title>Abstract</title> <p><bold>Aims:</bold>The aim of this study is to investigate the possible protective neuroprotective effects of gossypine (GOS) against cisplatin (CIS) (cis-diamminedichloroplatin [II]) toxicity. <bold>Materials and methods:</bold>CIS (In-vitro; 50 and 100 µM, In-vivo; 10 mg/kg/day) toxicity was created In-vitro and In-vivo, and GOS administration (In-vitro; 50, 75 and 100 µM, In-vivo; 5, 10 and 20 mg/kg/day). <bold>Key findings:</bold>We used different methods that supported each other. In primary neuron culture, cell proliferation was protected against CIS toxicity in a time-dependent manner with applying GOS. Oxidative/antioxidative markers were normalized in a dose-dependent manner with gossypin administration. In the mechanisms of neurotoxic/neuroprotective (iNOS/nNOS) and inhibition of inflammatory mediators (TNF-a and NF-kB), gossypin has been shown to inhibit NF-kB activation to suppress CIS-induced inflammation in primary neuron culture cells. It has been shown to have antiapoptotic effects in healthy tissues and cells by inhibiting CASP-3 and CASP-9 mRNA levels by regulating the ratio of BCL2/BAX, which are pro-apoptotic and anti-apoptotic indicators. <bold>Significance:</bold>We conclude that It has been shown that gossypin may be an ideal neuroprotective agent with potent antioxidant capacity and does not reduce the antitumor activity of the chemotherapeutic drug.</p>
dc.description.urihttps://doi.org/10.1007/s11033-025-10501-7
dc.description.urihttps://doi.org/10.21203/rs.3.rs-4647701/v1
dc.description.urihttps://pubmed.ncbi.nlm.nih.gov/40261449
dc.identifier.doi10.1007/s11033-025-10501-7
dc.identifier.eissn1573-4978
dc.identifier.issn0301-4851
dc.identifier.openairedoi_dedup___::842f99903e48e429184deaa85b1d536e
dc.identifier.pubmed40261449
dc.identifier.scopus2-s2.0-105003260022
dc.identifier.urihttps://hdl.handle.net/20.500.12597/41984
dc.identifier.volume52
dc.identifier.wos001472628800002
dc.language.isoeng
dc.publisherSpringer Science and Business Media LLC
dc.relation.ispartofMolecular Biology Reports
dc.rightsOPEN
dc.subjectMale
dc.subjectCell Survival
dc.subjectSuperoxide Dismutase
dc.subjectNF-kappa B
dc.subjectBrain
dc.subjectApoptosis
dc.subjectAntineoplastic Agents
dc.subjectGlutathione
dc.subjectAntioxidants
dc.subjectMice
dc.subjectOxidative Stress
dc.subjectNeuroprotective Agents
dc.subjectMalondialdehyde
dc.subjectAnimals
dc.subjectNeurotoxicity Syndromes
dc.subjectCisplatin
dc.subject.sdg3. Good health
dc.titleComparison of the neuroprotective effects of gossypin on cisplatin-induced neurotoxicity in vitro and in vivo
dc.typeArticle
dspace.entity.typePublication
local.api.response{"authors":[{"fullName":"Irfan, Cinar","name":"Irfan","surname":"Cinar","rank":1,"pid":null},{"fullName":"Muhammed, Yayla","name":"Muhammed","surname":"Yayla","rank":2,"pid":null},{"fullName":"Pınar, Bayram","name":"Pınar","surname":"Bayram","rank":3,"pid":null},{"fullName":"Damla, Binnetoğlu","name":"Damla","surname":"Binnetoğlu","rank":4,"pid":null}],"openAccessColor":"hybrid","publiclyFunded":false,"type":"publication","language":{"code":"eng","label":"English"},"countries":null,"subjects":[{"subject":{"scheme":"keyword","value":"Male"},"provenance":null},{"subject":{"scheme":"keyword","value":"Cell Survival"},"provenance":null},{"subject":{"scheme":"keyword","value":"Superoxide Dismutase"},"provenance":null},{"subject":{"scheme":"keyword","value":"NF-kappa B"},"provenance":null},{"subject":{"scheme":"keyword","value":"Brain"},"provenance":null},{"subject":{"scheme":"keyword","value":"Apoptosis"},"provenance":null},{"subject":{"scheme":"keyword","value":"Antineoplastic Agents"},"provenance":null},{"subject":{"scheme":"keyword","value":"Glutathione"},"provenance":null},{"subject":{"scheme":"keyword","value":"Antioxidants"},"provenance":null},{"subject":{"scheme":"SDG","value":"3. Good health"},"provenance":null},{"subject":{"scheme":"keyword","value":"Mice"},"provenance":null},{"subject":{"scheme":"keyword","value":"Oxidative Stress"},"provenance":null},{"subject":{"scheme":"keyword","value":"Neuroprotective Agents"},"provenance":null},{"subject":{"scheme":"keyword","value":"Malondialdehyde"},"provenance":null},{"subject":{"scheme":"keyword","value":"Animals"},"provenance":null},{"subject":{"scheme":"keyword","value":"Neurotoxicity Syndromes"},"provenance":null},{"subject":{"scheme":"keyword","value":"Cisplatin"},"provenance":null}],"mainTitle":"Comparison of the neuroprotective effects of gossypin on cisplatin-induced neurotoxicity in vitro and in vivo","subTitle":null,"descriptions":["<title>Abstract</title> <p><bold>Aims:</bold>The aim of this study is to investigate the possible protective neuroprotective effects of gossypine (GOS) against cisplatin (CIS) (cis-diamminedichloroplatin [II]) toxicity. <bold>Materials and methods:</bold>CIS (In-vitro; 50 and 100 µM, In-vivo; 10 mg/kg/day) toxicity was created In-vitro and In-vivo, and GOS administration (In-vitro; 50, 75 and 100 µM, In-vivo; 5, 10 and 20 mg/kg/day). <bold>Key findings:</bold>We used different methods that supported each other. In primary neuron culture, cell proliferation was protected against CIS toxicity in a time-dependent manner with applying GOS. Oxidative/antioxidative markers were normalized in a dose-dependent manner with gossypin administration. In the mechanisms of neurotoxic/neuroprotective (iNOS/nNOS) and inhibition of inflammatory mediators (TNF-a and NF-kB), gossypin has been shown to inhibit NF-kB activation to suppress CIS-induced inflammation in primary neuron culture cells. It has been shown to have antiapoptotic effects in healthy tissues and cells by inhibiting CASP-3 and CASP-9 mRNA levels by regulating the ratio of BCL2/BAX, which are pro-apoptotic and anti-apoptotic indicators. <bold>Significance:</bold>We conclude that It has been shown that gossypin may be an ideal neuroprotective agent with potent antioxidant capacity and does not reduce the antitumor activity of the chemotherapeutic drug.</p>"],"publicationDate":"2024-07-19","publisher":"Springer Science and Business Media LLC","embargoEndDate":null,"sources":["Crossref"],"formats":null,"contributors":null,"coverages":null,"bestAccessRight":{"code":"c_abf2","label":"OPEN","scheme":"http://vocabularies.coar-repositories.org/documentation/access_rights/"},"container":{"name":"Molecular Biology Reports","issnPrinted":"0301-4851","issnOnline":"1573-4978","issnLinking":null,"ep":null,"iss":null,"sp":null,"vol":"52","edition":null,"conferencePlace":null,"conferenceDate":null},"documentationUrls":null,"codeRepositoryUrl":null,"programmingLanguage":null,"contactPeople":null,"contactGroups":null,"tools":null,"size":null,"version":null,"geoLocations":null,"id":"doi_dedup___::842f99903e48e429184deaa85b1d536e","originalIds":["10501","10.1007/s11033-025-10501-7","50|doiboost____|638fb41ef26ab76cea6a036e1a5ca3a1","10.21203/rs.3.rs-4647701/v1","50|doiboost____|842f99903e48e429184deaa85b1d536e","40261449"],"pids":[{"scheme":"doi","value":"10.1007/s11033-025-10501-7"},{"scheme":"doi","value":"10.21203/rs.3.rs-4647701/v1"},{"scheme":"pmid","value":"40261449"}],"dateOfCollection":null,"lastUpdateTimeStamp":null,"indicators":{"citationImpact":{"citationCount":0,"influence":2.5349236e-9,"popularity":2.4744335e-9,"impulse":0,"citationClass":"C5","influenceClass":"C5","impulseClass":"C5","popularityClass":"C5"}},"instances":[{"pids":[{"scheme":"doi","value":"10.1007/s11033-025-10501-7"}],"license":"Springer Nature TDM","type":"Article","urls":["https://doi.org/10.1007/s11033-025-10501-7"],"publicationDate":"2025-04-22","refereed":"peerReviewed"},{"pids":[{"scheme":"doi","value":"10.21203/rs.3.rs-4647701/v1"}],"license":"CC BY","type":"Article","urls":["https://doi.org/10.21203/rs.3.rs-4647701/v1"],"publicationDate":"2024-07-19","refereed":"peerReviewed"},{"pids":[{"scheme":"pmid","value":"40261449"}],"alternateIdentifiers":[{"scheme":"doi","value":"10.1007/s11033-025-10501-7"}],"type":"Article","urls":["https://pubmed.ncbi.nlm.nih.gov/40261449"],"publicationDate":"2025-04-22","refereed":"nonPeerReviewed"}],"isGreen":false,"isInDiamondJournal":false}
local.import.sourceOpenAire
local.indexed.atWOS
local.indexed.atScopus
local.indexed.atPubMed

Dosyalar

Koleksiyonlar